{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:18:48Z","timestamp":1794622728366,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65796-8","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T15:51:44Z","timestamp":1764345104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation"],"prefix":"10.1038","volume":"16","author":[{"given":"Yazhou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshuo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanye","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaya","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8668-3601","authenticated-orcid":false,"given":"David","family":"Gennert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-6645","authenticated-orcid":false,"given":"Frank W.","family":"Pun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Aliper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9182","authenticated-orcid":false,"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5044-6568","authenticated-orcid":false,"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-1870","authenticated-orcid":false,"given":"Xiao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8966","authenticated-orcid":false,"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"65796_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"65796_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","volume":"145","author":"A Ashworth","year":"2011","unstructured":"Ashworth, A., Lord, C. J. & Reis-Filho, J. S. Genetic interactions in cancer progression and treatment. Cell 145, 30\u201338 (2011).","journal-title":"Cell"},{"key":"65796_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","volume":"22","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi, N. Y. L. et al. Synthetic lethal strategies for the development of cancer therapeutics. Nat. Rev. Clin. Oncol. 22, 46\u201364 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65796_CR4","doi-asserted-by":"publisher","first-page":"116547","DOI":"10.1016\/j.ejmech.2024.116547","volume":"275","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity. Eur. J. Med. Chem. 275, 116547 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"65796_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127\u2013132 (2008).","journal-title":"Nat. Biotechnol."},{"key":"65796_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg.2017.47","volume":"18","author":"NJ O\u2019Neil","year":"2017","unstructured":"O\u2019Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18, 613\u2013623 (2017).","journal-title":"Nat. Rev. Genet."},{"key":"65796_CR7","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1038\/onc.2012.504","volume":"32","author":"JPH Chow","year":"2013","unstructured":"Chow, J. P. H. & Poon, R. Y. C. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 32, 4778\u20134788 (2013).","journal-title":"Oncogene"},{"key":"65796_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","volume":"604","author":"D Gallo","year":"2022","unstructured":"Gallo, D. et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 604, 749\u2013756 (2022).","journal-title":"Nature"},{"key":"65796_CR9","doi-asserted-by":"publisher","first-page":"PR008","DOI":"10.1158\/1535-7163.TARG-23-PR008","volume":"22","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A. Mol. Cancer Ther. 22, PR008 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"65796_CR10","doi-asserted-by":"publisher","first-page":"104324","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa, R. et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit. Rev. Oncol. Hematol. 196, 104324 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"65796_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.molmed.2024.12.009","volume":"31","author":"L Arrizabalaga","year":"2025","unstructured":"Arrizabalaga, L., Garc\u00eda-Torralba, E., Galluzzi, L. & Buqu\u00e9, A. Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer. Trends Mol. Med. 31, 495\u2013497 (2025).","journal-title":"Trends Mol. Med."},{"key":"65796_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00270-2","volume":"9","author":"YP Kok","year":"2020","unstructured":"Kok, Y. P. et al. Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis 9, 88 (2020).","journal-title":"Oncogenesis"},{"key":"65796_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1126\/science.1065203","volume":"294","author":"DM Koepp","year":"2001","unstructured":"Koepp, D. M. et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294, 173\u2013177 (2001).","journal-title":"Science"},{"key":"65796_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/35095076","volume":"413","author":"H Strohmaier","year":"2001","unstructured":"Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316\u2013322 (2001).","journal-title":"Nature"},{"key":"65796_CR15","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1158\/2767-9764.CRC-23-0306","volume":"3","author":"S O\u2019Brien","year":"2023","unstructured":"O\u2019Brien, S. et al. FBXW7-loss sensitizes cells to ATR inhibition through induced mitotic catastrophe. Cancer Res. Commun. 3, 2596\u20132607 (2023).","journal-title":"Cancer Res. Commun."},{"key":"65796_CR16","doi-asserted-by":"publisher","first-page":"17997","DOI":"10.1021\/acs.jmedchem.4c01619","volume":"67","author":"M Yang","year":"2024","unstructured":"Yang, M., Xiang, H. & Luo, G. Targeting protein kinase, membrane-associated Tyrosine\/Threonine 1 (PKMYT1) for precision cancer therapy: from discovery to clinical trial. J. Med. Chem. 67, 17997\u201318016 (2024).","journal-title":"J. Med. Chem."},{"key":"65796_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"65796_CR18","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","volume":"121","author":"RA Ward","year":"2020","unstructured":"Ward, R. A. et al. Challenges and opportunities in cancer drug resistance. Chem. Rev. 121, 3297\u20133351 (2020).","journal-title":"Chem. Rev."},{"key":"65796_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01469-6","volume":"20","author":"Y He","year":"2021","unstructured":"He, Y. et al. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Mol. Cancer 20, 156 (2021).","journal-title":"Mol. Cancer"},{"key":"65796_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem, G. M. & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181, 102\u2013114 (2020).","journal-title":"Cell"},{"key":"65796_CR21","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1038\/s41557-024-01660-4","volume":"16","author":"J Farnung","year":"2024","unstructured":"Farnung, J. & Schulman, B. A. Ubiquitin is a chemist\u2019s playground. Nat. Chem. 16, 1918 (2024).","journal-title":"Nat. Chem."},{"key":"65796_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas, D., Hornberger, K. R. & Crews, C. M. Protein degraders enter the clinic - a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 20, 265\u2013278 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"65796_CR23","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"65796_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cbpa.2019.07.003","volume":"52","author":"C Maniaci","year":"2019","unstructured":"Maniaci, C. & Ciulli, A. Bifunctional chemical probes inducing protein-protein interactions. Curr. Opin. Chem. Biol. 52, 145\u2013156 (2019).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"65796_CR25","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","volume":"14","author":"RP Nowak","year":"2018","unstructured":"Nowak, R. P. et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat. Chem. Biol. 14, 706\u2013714 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"65796_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a Promiscuous Warhead. Cell Chem. Biol. 25, 78\u201387 (2018).","journal-title":"Cell Chem. Biol."},{"key":"65796_CR27","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1039\/D2CS00200K","volume":"51","author":"RG Guenette","year":"2022","unstructured":"Guenette, R. G. et al. Target and tissue selectivity of PROTAC degraders. Chem. Soc. Rev. 51, 5740\u20135756 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"65796_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","volume":"16","author":"TM Nguyen","year":"2024","unstructured":"Nguyen, T. M. et al. Proteolysis-targeting chimeras with reduced off-targets. Nat. Chem. 16, 218\u2013228 (2024).","journal-title":"Nat. Chem."},{"key":"65796_CR29","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","volume":"67","author":"M Schade","year":"2024","unstructured":"Schade, M. et al. Structural and physicochemical features of oral PROTACs. J. Med. Chem. 67, 13106\u201313116 (2024).","journal-title":"J. Med. Chem."},{"key":"65796_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1021\/acs.jcim.2c01191","volume":"63","author":"YA Ivanenkov","year":"2023","unstructured":"Ivanenkov, Y. A. et al. Chemistry42: an AI-driven platform for molecular design and optimization. J. Chem. Inf. Model. 63, 695\u2013701 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"65796_CR31","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1021\/acs.accounts.2c00479","volume":"55","author":"BA Lanman","year":"2022","unstructured":"Lanman, B. A., Parsons, A. T. & Zech, S. G. Addressing Atropisomerism in the development of Sotorasib, a Covalent Inhibitor of KRAS G12C: structural, analytical, and synthetic considerations. Acc. Chem. Res. 55, 2892\u20132903 (2022).","journal-title":"Acc. Chem. Res."},{"key":"65796_CR32","doi-asserted-by":"publisher","first-page":"16388","DOI":"10.1021\/acs.jmedchem.3c01848","volume":"66","author":"S Norris","year":"2023","unstructured":"Norris, S. et al. Design and synthesis of novel cereblon binders for use in targeted protein degradation. J. Med. Chem. 66, 16388\u201316409 (2023).","journal-title":"J. Med. Chem."},{"key":"65796_CR33","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1021\/acs.jcim.8b00872","volume":"59","author":"ML Drummond","year":"2019","unstructured":"Drummond, M. L. & Williams, C. I. In silico modeling of PROTAC-mediated ternary complexes: validation and application. J. Chem. Inf. Model. 59, 1634\u20131644 (2019).","journal-title":"J. Chem. Inf. Model."},{"key":"65796_CR34","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1021\/acs.jcim.0c00897","volume":"60","author":"ML Drummond","year":"2020","unstructured":"Drummond, M. L., Henry, A., Li, H. & Williams, C. I. Improved accuracy for modeling PROTAC-mediated ternary complex formation and targeted protein degradation via new in silico methodologies. J. Chem. Inf. Model. 60, 5234\u20135254 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"65796_CR35","doi-asserted-by":"publisher","first-page":"101062","DOI":"10.1016\/j.xcrp.2022.101062","volume":"3","author":"X Han","year":"2022","unstructured":"Han, X. & Sun, Y. Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy. Cell Rep. Phys. Sci. 3, 101062 (2022).","journal-title":"Cell Rep. Phys. Sci."},{"key":"65796_CR36","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","volume":"66","author":"KR Hornberger","year":"2023","unstructured":"Hornberger, K. R. & Araujo, E. M. V. Physicochemical property determinants of oral absorption for PROTAC protein degraders. J. Med. Chem. 66, 8281\u20138287 (2023).","journal-title":"J. Med. Chem."},{"key":"65796_CR37","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","volume":"67","author":"X Zheng","year":"2024","unstructured":"Zheng, X. et al. Discovery of KT-474\u2013a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases. J. Med. Chem. 67, 18022\u201318037 (2024).","journal-title":"J. Med. Chem."},{"key":"65796_CR38","doi-asserted-by":"publisher","first-page":"ND09","DOI":"10.1158\/1538-7445.AM2022-ND09","volume":"82","author":"KL Jackson","year":"2022","unstructured":"Jackson, K. L. et al. Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers. Cancer Res. 82, ND09 (2022).","journal-title":"Cancer Res."},{"key":"65796_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12020-023-03362-2","volume":"81","author":"E Acitelli","year":"2023","unstructured":"Acitelli, E., Maiorca, C., Grani, G. & Maranghi, M. Metabolic adverse events of multitarget kinase inhibitors: a systematic review. Endocrine 81, 16\u201329 (2023).","journal-title":"Endocrine"},{"key":"65796_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder, S., Sharma, U. C. & Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct. Target. Ther. 8, 262 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"65796_CR41","doi-asserted-by":"publisher","first-page":"903532","DOI":"10.3389\/fonc.2022.903532","volume":"12","author":"C Colombo","year":"2022","unstructured":"Colombo, C. et al. Daily management of patients on multikinase inhibitors\u2019 treatment. Front. Oncol. 12, 903532 (2022).","journal-title":"Front. Oncol."},{"key":"65796_CR42","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1021\/acs.jmedchem.7b00996","volume":"60","author":"J-Y Zhu","year":"2017","unstructured":"Zhu, J.-Y. et al. Structural basis of Wee kinases functionality and inactivation by diverse small molecule inhibitors. J. Med. Chem. 60, 7863\u20137875 (2017).","journal-title":"J. Med. Chem."},{"key":"65796_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"65796_CR44","doi-asserted-by":"publisher","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","volume":"65","author":"J Szychowski","year":"2022","unstructured":"Szychowski, J. et al. Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306. J. Med. Chem. 65, 10251\u201310284 (2022).","journal-title":"J. Med. Chem."},{"key":"65796_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jcc.22885","volume":"33","author":"T Lu","year":"2012","unstructured":"Lu, T. & Chen, F. Multiwfn: A multifunctional wavefunction analyzer. J. Comput. Chem. 33, 580\u2013592 (2012).","journal-title":"J. Comput. Chem."},{"key":"65796_CR46","doi-asserted-by":"publisher","first-page":"082503","DOI":"10.1063\/5.0216272","volume":"161","author":"T Lu","year":"2024","unstructured":"Lu, T. A comprehensive electron wavefunction analysis toolbox for chemists. Multiwfn. J. Chem. Phys. 161, 082503 (2024).","journal-title":"Multiwfn. J. Chem. Phys."},{"key":"65796_CR47","unstructured":"Tian Lu, Sobtop, Version 1.0 (dev5), http:\/\/sobereva.com\/soft\/Sobtop (accessed on 1, 2025)."},{"key":"65796_CR48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13321-021-00548-6","volume":"13","author":"C Bouysset","year":"2021","unstructured":"Bouysset, C. & Fiorucci, S. ProLIF: a library to encode molecular interactions as fingerprints. J Cheminform 13, 72 (2021).","journal-title":"J Cheminform"},{"key":"65796_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/ci500588j","volume":"55","author":"T Sander","year":"2015","unstructured":"Sander, T., Freyss, J., von Korff, M. & Rufener, C. DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis. J. Chem. Inf. Model. 55, 460\u2013473 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"65796_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"65796_CR51","unstructured":"UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51, D523\u2013D531 (2023)."},{"key":"65796_CR52","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/nprot.2007.194","volume":"2","author":"E Weerapana","year":"2007","unstructured":"Weerapana, E., Speers, A. E. & Cravatt, B. F. Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)-a general method for mapping sites of probe modification in proteomes. Nat Protoc 2, 1414\u20131425 (2007).","journal-title":"Nat Protoc"},{"key":"65796_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","volume":"15","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M. & Cravatt, B. F. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat. Chem. Biol. 15, 737\u2013746 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"65796_CR54","doi-asserted-by":"publisher","first-page":"D1539","DOI":"10.1093\/nar\/gkac1040","volume":"51","author":"EW Deutsch","year":"2023","unstructured":"Deutsch, E. W. et al. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res 51, D1539\u2013D1548 (2023).","journal-title":"Nucleic Acids Res"},{"key":"65796_CR55","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res"},{"key":"65796_CR56","doi-asserted-by":"publisher","first-page":"565644","DOI":"10.3389\/fphar.2020.565644","volume":"11","author":"D Polykovskiy","year":"2020","unstructured":"Polykovskiy, D. et al. Molecular Sets (MOSES): a benchmarking platform for molecular generation models. Front. Pharmacol. 11, 565644 (2020).","journal-title":"Front. Pharmacol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65796-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65796-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65796-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:02:40Z","timestamp":1764349360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65796-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65796"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65796-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Insilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development that is engaged in drug discovery programs for aging, fibrosis, and oncology. Insilico Medicine has filed patent applications, including the compounds described herein [(1) Ding, X. et al. Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (PKMYT1) inhibitors and uses thereof. WO2023155870, published online 24 Aug 2023; (2) Ding, X. et al. Bifunctional compounds for targeting PKMYT1 and methods of use. WO2025040132, published online 27 Feb, 2025]. Insilico Medicine owns the whole patent rights. All authors are current employees of Insilico Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10759"}}